Drug Details
General Information of the Drug (ID: DR6763) | ||||
---|---|---|---|---|
Name |
Dexamethasone
|
|||
Synonyms |
Decadron; Dexamethazone; Maxidex; Prednisolone F; Decaspray; Desametasone; Hexadecadrol; Hexadrol; Dexasone; Oradexon; Dexacort; Deltafluorene; Superprednol; Visumetazone; Mediamethasone; Desamethasone; Dergramin; Mymethasone; Dinormon; Dexapolcort; Dexalona; Desameton; Desadrene; Cortisumman; Aphtasolon; Turbinaire; Dextelan; Dexameth; Decaderm; Millicorten; Gammacorten; Fortecortin; Dexadeltone; Dekacort; Dectancyl; Decasone; Dexason; Mexidex; Dexone; Calonat; Corsone; Auxiron; Fluormethylprednisolone; Azium; Dexa-Cortisyl
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Rheumatoid arthritis [ICD-11: FA20] | Approved | [1] | |
Structure |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C22H29FO5
|
|||
PubChem CID | ||||
Canonical SMILES |
CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C
|
|||
InChI |
1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1
|
|||
InChIKey |
UREBDLICKHMUKA-CXSFZGCWSA-N
|
|||
CAS Number |
CAS 50-02-2
|
|||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Genistein | Glycine max | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
|
In-vitro Model | COLO 320 | CVCL_1989 | Colon adenocarcinoma | Homo sapiens | ||
Experimental
Result(s) |
The combined effects of dexamethasone and genistein on the induction of p21 protein and activation of p21 promoter were synergistic. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Glucocorticoid receptor (NR3C1) | Molecule Info | [3] | |
KEGG Pathway | Neuroactive ligand-receptor interaction | Click to Show/Hide | ||
NetPath Pathway | IL2 Signaling Pathway | Click to Show/Hide | ||
2 | TCR Signaling Pathway | |||
Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | Click to Show/Hide | ||
2 | Signaling events mediated by HDAC Class II | |||
3 | FOXA2 and FOXA3 transcription factor networks | |||
4 | Glucocorticoid receptor regulatory network | |||
5 | Regulation of Androgen receptor activity | |||
6 | AP-1 transcription factor network | |||
Reactome | BMAL1:CLOCK,NPAS2 activates circadian gene expression | Click to Show/Hide | ||
WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | Click to Show/Hide | ||
2 | SIDS Susceptibility Pathways | |||
3 | Nuclear Receptors Meta-Pathway | |||
4 | Endoderm Differentiation | |||
5 | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
6 | Adipogenesis | |||
7 | Circadian Clock | |||
8 | Nuclear Receptors |